Table 3.

Crude and adjusted HR for cancer and aneuploidy by bleomycin sensitivity

No. breaksCancer
Aneuploidy
EventsnCrude HR (95% CI)PAdjusted HR*PEventsnCrude HRPAdjusted HR*P
≤0.6101101.01.07931.01.0
>0.6171091.60 (0.74-3.51)0.241.63 (0.71-3.75)0.2516872.44 (1.00-5.93)<0.053.71 (1.44-9.53)0.006
≤0.8161551.01.0121291.01.0
>0.811641.86 (0.85-4.06)0.121.74 (0.74-4.09)0.2011512.41 (1.06-5.47)0.044.02 (1.64-9.85)0.002
<0.445501.01.02431.01.0
≥0.44,<0.65551.17 (0.33-4.09)0.811.20 (0.34-4.23)0.774461.98 (0.36-10.8)0.431.90 (0.34-10.54)0.46
≥0.6,<0.878591.31 (0.43-4.01)0.641.44 (0.45-4.61)0.547473.19 (0.66-15.4)0.154.11 (0.81-20.71)0.09
≥0.879552.03 (0.67-6.18)0.211.98 (0.61-6.41)0.2510445.33 (1.17-24.3)0.0310.72 (2.19-52.52)0.003
  • NOTE: The first row of each set of comparisons summarizes the reference groups [patients with ≤0.6, ≤0.8, and in the first quartile of bleomycin breaks (<0.44 breaks per cell)], and the subsequent rows summarize the outcomes and HRs with respect to the reference groups.

  • * HRs and 95% CIs are adjusted for age, gender (M/F), waist-to-hip ratio (low/high), tobacco use (never/ever), and nonsteroidal anti-inflammatory drug use (current/former/never). Waist-to-hip median was calculated with respect to gender.

  • Reference group.